

**Imatinib Mesylate (Glivec®)
Novartis**

No. 01/02

Summary of Recommendation

8 March 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs that a Category 2 Recommendation has been allocated to this product. The recommendation is summarised as follows:

ADVICE

Category 2: Recommended for restricted use within the NHS in Scotland.

Approved for treatment of chronic myeloid leukaemia under the overall supervision of haematologists/oncologists, within the context of the current guidelines on this medicine issued by the British Society of Haematology (November 2001).

REASONS FOR ADVICE

Imatinib is the first treatment to offer major cytogenetic responses in chronic myeloid leukaemia. This approach appears to provide a significant advance in the treatment of a hitherto fatal haematological malignancy.

Professor David H Lawson
Chairman